Evidence mapPaperPMID 34947895Full record

ReviewLife (Basel, Switzerland)2021

Update on Statin Treatment in Patients with Neuropsychiatric Disorders.

Razieh Avan, Adeleh Sahebnasagh, Javad Hashemi, Mahila Monajati, Fatemeh Faramarzi, Neil C Henney, Fabrizio Montecucco, Tannaz Jamialahmadi, Amirhossein Sahebkar

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Brain sciences · 2022
    Article
  12. Review
  13. Review
  14. Observational
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Razieh AvanDepartment of Clinical Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), School of Pharmacy, Birjand University of Medical Sciences, Birjand 9717853577, Iran.
Adeleh SahebnasaghClinical Research Center, Department of Internal Medicine, North Khorasan University of Medical Sciences, Bojnurd 9453155166, Iran.
Javad HashemiDepartment of Pathobiology and Laboratory Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd 9453155166, Iran.
Mahila MonajatiDepartment of Internal Medicine, Golestan University of Medical Sciences, Gorgan 4934174515, Iran.
Fatemeh FaramarziClinical Pharmacy Research Center, Iran University of Medical Sciences, Tehran 1445613131, Iran.
Neil C HenneyPharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 5UX, UK.ORCID 0000-0002-2834-1566
Fabrizio MontecuccoIRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network, 10 Largo Benzi, 16132 Genoa, Italy.ORCID 0000-0003-0823-8729
Tannaz JamialahmadiDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.ORCID 0000-0002-8656-1444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuropsychiatric disorders. In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of electronic databases. We also explored the adverse effects of these drugs to obtain insights into the benefits and risks associated with their use in the treatment of these disorders. Lipophilic statins (including simvastatin) because of better brain penetrance may have greater protective effects against MDD and schizophrenia. The significant positive effects of statins in the treatment of anxiety disorders without any serious adverse side effects were shown in numerous studies. In OCD, BD, and delirium, limitations, and contradictions in the available data make it difficult to draw conclusions on any positive effect of statins. The positive effects of simvastatin in autism disorders have been evaluated in only a small number of clinical trials. Although some studies showed positive effect of statins in some neuropsychiatric disorders, further prospective studies are needed to confirm this and define the most effective doses and treatment durations.

Indexed as

adverse effectsanxietyautism spectrum disordersbipolar disorderclinical trialsdeliriummajor depressive disorderneuropsychiatric disordersobsessive-compulsive disorderschizophreniastatins

Identifiers

PMID34947895
PMCPMC8703562

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.